{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:29:33Z","timestamp":1793896173891,"version":"4.8.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U19AI095219"],"award-info":[{"award-number":["5U19AI095219"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K24AI180296"],"award-info":[{"award-number":["5K24AI180296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.anai.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:28:23Z","timestamp":1749320903000},"page":"366-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Aspirin-exacerbated respiratory disease in the era of biologics"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6709-9795","authenticated-orcid":false,"given":"Tanya M.","family":"Laidlaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anai.2025.06.001_bib0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.001_bib0002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/alr.22249","article-title":"Patterns of olfactory dysfunction in chronic rhinosinusitis identified by hierarchical cluster analysis and machine learning algorithms","volume":"9","author":"Morse","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0003","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/alr.22264","article-title":"Long-term revision rates for endoscopic sinus surgery","volume":"9","author":"Smith","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.001_bib0004","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/000348941112000304","article-title":"Revision rates after endoscopic sinus surgery: a recurrence analysis","volume":"120","author":"Mendelsohn","year":"2011","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5 Pt 1","key":"10.1016\/j.anai.2025.06.001_bib0005","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025","article-title":"Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects","volume":"143","author":"Christie","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.anai.2025.06.001_bib0006","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D\u2082: a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.001_bib0007","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaci.2018.10.007","article-title":"Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease","volume":"143","author":"Cahill","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.001_bib0008","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1164\/ajrccm.153.1.8542168","article-title":"Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects","volume":"153","author":"Nasser","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2025.06.001_bib0009","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2005.10.037","article-title":"Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells","volume":"117","author":"Ying","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.001_bib0010","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5R\u03b1 marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0011","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/ajra.2014.28.4054","article-title":"Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease","volume":"28","author":"Johns","year":"2014","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0012","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI620","article-title":"Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma","volume":"101","author":"Cowburn","year":"1998","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.anai.2025.06.001_bib0013","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jaip.2024.01.029","article-title":"Absolute eosinophil counts in aspirin-exacerbated respiratory disease are distinctly elevated and correlate inversely with respiratory function","volume":"12","author":"Supron","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2025.06.001_bib0014","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/lary.27564","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2019","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.anai.2025.06.001_bib0015","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL- 5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.anai.2025.06.001_bib0016","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1111\/all.16218","article-title":"Human nasal epithelial cells express IL-5R\u03b1 but not the co-receptor CSF2RB and do not signal to IL-5","volume":"79","author":"Sohail","year":"2024","journal-title":"Allergy"},{"issue":"16","key":"10.1016\/j.anai.2025.06.001_bib0017","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.anai.2025.06.001_bib0018","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.anai.2025.06.001_bib0019","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2025.06.001_bib0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1081-1206(10)61803-0","article-title":"Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"90","author":"Berges-Gimeno","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0021","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease","volume":"32","author":"Walters","year":"2018","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0022","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2020.08.025","article-title":"Impact of reported NSAID \u201callergies\u201d on opioid use disorder in back pain","volume":"147","author":"Li","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.06.001_bib0023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"10.1016\/j.anai.2025.06.001_bib0024","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2025.06.001_bib0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2021.08.015","article-title":"Eicosanoid dysregulation and type 2 inflammation in AERD","volume":"148","author":"Mullol","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0026","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2020.11.001","article-title":"Inflammatory heterogeneity in aspirin-exacerbated respiratory disease","volume":"147","author":"Scott","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.001_bib0027","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2024.04.020","article-title":"IL-4R\u03b1 signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease","volume":"154","author":"Chen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2025.06.001_bib0028","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0029","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of Benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2025.06.001_bib0031","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/bcp.16087","article-title":"Pharmacokinetics\/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial","volume":"90","author":"Emson","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.001_bib0032","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2025.06.001_bib0033","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series","volume":"9","author":"Martin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.06.001_bib0034","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.001_bib0035","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.001_bib0036","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.001_bib0037","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.anai.2025.06.001_bib0038","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10209","key":"10.1016\/j.anai.2025.06.001_bib0039","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2025.06.001_bib0040","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.06.001_bib0041","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.001_bib0042","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2021.11.020","article-title":"Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Patel","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.001_bib0043","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01335-2022","article-title":"Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease","volume":"61","author":"Schneider","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.anai.2025.06.001_bib0044","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","article-title":"Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease","volume":"126","author":"Mustafa","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.001_bib0045","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2025.06.001_bib0046","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2025.06.001_bib0047","doi-asserted-by":"crossref","unstructured":"Laidlaw TM, Buchheit KM, Cahill KN, Bernstein JA, Martin NL, Roseti SL, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR [e-pub ahead of print]. J Allergy Clin Immunol Pract. doi:10.1016\/j.jaip.2025.03.033, accessed May 30, 2025.","DOI":"10.1016\/j.jaip.2025.03.033"},{"key":"10.1016\/j.anai.2025.06.001_bib0048","article-title":"Tezepelumab improved chronic rhinosinusitis with nasal polyps in a patient with aspirin exacerbated respiratory disease","volume":"50","author":"Yamashita","year":"2024","journal-title":"Respir Med Case Rep"},{"issue":"12","key":"10.1016\/j.anai.2025.06.001_bib0049","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/cea.14157","article-title":"Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life","volume":"52","author":"Tchekmedyian","year":"2022","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"10.1016\/j.anai.2025.06.001_bib0050","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jama.2020.1012","article-title":"Changes list prices, net prices, and discounts for branded drugs in the US, 2007-2018","volume":"323","author":"Hernandez","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.anai.2025.06.001_bib0051","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/alr.21496","article-title":"Identification of chronic rhinosinusitis phenotypes using cluster analysis","volume":"5","author":"Soler","year":"2015","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625002777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625002777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:13:06Z","timestamp":1759299186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625002777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1081120625002777"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.001","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin-exacerbated respiratory disease in the era of biologics","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}